EVALUATION OF THE PRESENCE OF SstI POLYMORPHISM OF C-III APOLIPOPROTEIN AND ITS ASSOCIATION WITH TRIGLYCERIDE LEVELS IN A DIABETIC SAMPLE FROM SOUTHERN BRAZIL
DOI:
https://doi.org/10.13037/ras.vol13n46.3178Keywords:
Apolipoprotein C, diabetes mellitus, triglyceridesAbstract
Introduction: Type 2 diabetes mellitus (DM2) is the most common metabolic disease. Objective: Toinvestigate the presence of the SstI polymorphism of the C-III apolipoprotein and verify the associationwith the lipid profile in a diabetic sample from Southern Brazil. Materials and methods: Sixty-fivepatients with DM2 were subjected to anthropometric measurements, lipid profile and polymorphismanalyses. The SstI polymorphism of APO C-III was made using the polymerase chain reaction methodfollowed by enzymatic digestion (PCR-RFLP). Fragments that showed a size of 269 base pairs (bp) and159 bp were classified as G allele, and fragments that showed a size of 428 bp were classified as C allele.We used the Student t test to compare the means of the lipid profile between men and women while thepolymorphism analysis was performed using the chi-square test (?2) and the Fisher exact test Results:The mean age was 64.67±8.74 and BMI was 1.09±4.86 kg/m2. Of the 65 individuals, 55% did not useantilipemic medication. The rate of total cholesterol, triglycerides, HDL and LDL levels were withinnormal limits. Regarding polymorphism, 80% of the subjects had normal genotype (CC), 3.1% changedgenotype (GG), and 16.9% altered genotype (CG). There was no significant association between CCgenotype and triglyceride levels below 200 mg/dL. Conclusion: In the evaluated population, the majorityof the individuals presented a normal genotype to the SstI polymorphism with no association with thetriglycerides rate.Downloads
References
Gross JL, Silveiro SP, Camargo JL, Reicheltz AJ, Azevedo MJ. Diabetes Melito: Diagnóstico, Classificação e Avaliação do Controle Glicêmico. Arq Bras Endocrinol Metab. 2002;46(1):16-26.
World Health Organization. Diabetes mellitus Fact sheets. 2002. [acessado 2011 set 05]; Disponível em: <http://www.who.int/ inf-fs/en/fact138.html>.
Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes. Estimates for the year 2000 and projections for 2030. Diabtes Care. 2005.
Wellen KE, Hotamisligil G.S. Inflammation, stress and diabetes. J. Clin. Invest. 2005;115:1111-1119.
Malerbi DA, Franco LJ. Multicenter study of the prevalence of diabetes mellitus and impaired glucose tolerance in the urban Brazilian population aged 30-69yr. The Brazilian cooperative group on the study of diabetes prevalence. Diabetes care. 1992.
Yamada T, Sato A, Nishimori T, Mitsuhashi T, Terao A, Sagai H et al. Importance of hypercoagulability over hyperglycemia for vascular complication in type 2 diabetes. Diabetes Res Clin Prac. 2000;49(1):23-31.
Mcqueen MJ Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J et al. Lipids, lipoproteins and apolipoproteins as risk markers of myocardial infarction in 52 countries. Interheart study. 2008.
Lima LM, Carvalho MDG, Soares AL, Lasmar MC, Novelli BA, Sousa MO. Correlação entre os níveis plasmáticos de apolipoproteínas A-I e B e o perfil lipídico em indivíduos com e sem diabetes mellitus tipo 2 e hipertensão arterial. 2005;41(6):411-417.
Motta VT. Bioquímica clínica para o laboratório: princípios e interpretações. São Paulo:Missau; 2003.
Parzianello L, Oliveira G, Coelho JC. Apolipoprotein CIII polymorphism and triglyceride levels of a Japanese population living in the southern Brazil. Brazilian Journal of medical and biological Research. 2008;41:462-467.
Lima E, Couto D. Estrutura, metabolismo e funções fisiológicas da lipoprotepina de alta densidade. J Bras Patol Med Lab. 2006;42(3):169-178.
Young CE, Karas RH, Kuvin JT. High-density lipoprotein cholesterol and coronary heart disease. Cardiol Rev. 2004;12(2):107-19.
Fiegenbaum M, Andrade FM de, Hutz MH. Association between plasma lipid parameters and APOC3 genotypes in Brazilian subjects: Effect of gender, smoking and APOE genotypes Clinica Chimica Acta. 2007;380:175-181.
World Health Organization. Obesity Preventing and managing the Global Epidemic. Report of a WHO Consultation on Obesity. Geneva.1998.
BRASIL. IV Diretrizes Brasileiras sobre Dislipidemias e Diretriz de Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade brasileira de Cardiologia. Arquivo brasileiro de cardiologia. São Paulo. 2007.
Lahiri DK, Nurnberger JIJR. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Research. 1991;19:5444-5444.
Souza LJ, Chalita FEB, Reis AFF, Teixeira CL, Gicovate Neto C, Bastos DA et al. Prevalência de Diabetes Mellitus e Fatores de Risco em Campos dos Goytacazes, RJ. Arq Bras Endocrinol Metab. 2003;47(1).
Mota APL, Carvalho MdasG, Lima LM, Santos MERdeC, Sousa MdeO. Lipoproteina (a) em pacientes portadores de doenca arterial obstrutiva periferica e/ou diabetes mellitus tipo 2. J Bras Patol Med Lab. 2008;44(2):89-95.
Vasques AC J, Pereira PF, Gomide RM, Batista MCR, Campos MTFS, Sant’Ana LFR et al. Influência do Excesso de Peso Corporal e da Adiposidade Central na Glicemia e no Perfil Lipídico de Pacientes Portadores de Diabetes Mellitus Tipo 2. Arq Bras Endocrinol Metab. 2007;51(9).
Bevilacqua MR, Gimeno SGA, Matsumura LK, Ferreira SRG. Hiperlipidemias e Fatores Dietéticos: Estudo Transversal Entre Nipo-Brasileiros. Arq Bras Endocrinol Metab. 2007;51(4).
Novak EM, Bydlowski PS. Biologia molecular nas dislipidemias. Arq Bras Cardiol. 1996;67(6).
Haynes W. Triglyceride-rich lipoproteins and vascular function. Arteriosc Thromb Vasc Biol 2003; 23: 153-5.
Batal R, Tremblay M, Barrett PH, Jacques H, Fredenrich A, Mamer O, Davignon J, Cohn JS. Plasma kinetics of apoC-III and apoE in normolipidemic and hypertriglyceridemic subjects. J Lipid Res. 2000;41:706–718.
Maeda N, Li H, Lee D, Oliver P, Quarfordt SH, Osada J. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia. J Biol Chem. 1994; 269:23610 –23616.
Holmberger R, Refai E, Höög A, Crooked RM, Grahamd M, Olivecronae G et al. Lowering apolipoprotein CIII delays onset of type 1 diabetes. PNAS. 2011; 108.
Shoulders CC, Grantham TT, North JD. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children.Hum Genet 1996; 98: 557– 566.
Pezzi N, Bazzo , Matte MCC, Fiengenbaum M. Influência de polimorfismos nos genes APO CIII e CYP2B6 no perfil lipídico de pacientes HIV positivos sob terapia antirretroviral. Arq Bras Cardiol. 2011; 97 (2): 279-85.
Izar MC, Helfenstein FA, Ihara SSM. Fatores de Risco, Marcadores Bioquímicos e Polimorfismos Genéticos na Doença Arterial Coronariana Prematura. Arq Bras Cardiol. 2003; 80(4): 379-87.
Downloads
Published
Issue
Section
License
Policy Proposal for Journals offering Free Delayed Access
Authors who publish in this magazine agree to the following terms:
- Authors maintain the copyright and grant the journal the right to the first publication, with the work simultaneously licensed under a Creative Commons Attribution License after publication, allowing the sharing of the work with recognition of the authorship of the work and initial publication in this journal.
- Authors are authorized to assume additional contracts separately, for non-exclusive distribution of the version of the work published in this magazine (eg, publishing in institutional repository or as a book chapter), with the acknowledgment of the authorship and initial publication in this journal.
- Authors are allowed and encouraged to publish and distribute their work online (eg in institutional repositories or on their personal page) at any point before or during the editorial process, as this can generate productive changes, as well as increase impact and citation of the published work (See The Effect of Open Access).
